Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Clinical Practice Guidelines – Newly Diagnosed and Relapsed Follicular Lymphoma

Newly Diagnosed and Relapsed Follicular Lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Published in 2020 – Ann Oncol (2020)
Authors: M. Dreyling, M. Ghielmini, S. Rule, G. Salles, M. Ladetto, S. H. Tonino, K. Herfarth, J.F. Seymour & M. Jerkeman, on behalf of the ESMO Guidelines Committee

Follicular lymphomas are the second most frequent subtype of nodal lymphoid malignancies in Western Europe. The annual incidence of this disease is rare but has increased during recent decades. The updated ESMO Clinical Practice Guidelines on newly diagnosed and relapsed follicular lymphoma cover diagnosis, staging and risk assessment, treatment recommendations, innovative approaches, personalised medicine, follow-up and long-term implications and survivorship.

These Clinical Practice Guidelines are endorsed by the European Hematology Association (EHA)

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.